Sign Up Today and Learn More About Purespring Therapeutics Stock
Invest in or calculate the value of your shares in Purespring Therapeutics or other pre-IPO companies through EquityZen's platform.
Purespring Therapeutics Stock (PUTH)
Purespring Therapeutics is a gene therapy company that provides treatments for different kidney diseases.
About Purespring Therapeutics Stock
Founded
2020
Industries
Software, Artificial Intelligence, Data and Analytics
Purespring Therapeutics Press Mentions
Stay in the know about the latest news on Purespring Therapeutics
Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN)
biospace • Apr 28, 2025
Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN)
globenewswire • Apr 28, 2025
Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN)
einpresswire • Apr 28, 2025
Purespring’s PS-002 designated orphan drug for IgA nephropathy
bioworld • Apr 28, 2025
Polynucleotides, aav vectors, and pharmaceutical compositions for treating …
patents • Apr 02, 2025
Purespring Therapeutics Management
Leadership team at Purespring Therapeutics
Board Member
Maina Bhaman
Board Member
Sonia Hallen
Join now and verify your accreditation status to gain access to:
- Purespring Therapeutics Current Valuation
- Purespring Therapeutics Stock Price
- Purespring Therapeutics Management
- Available deals in Purespring Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Purespring Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Purespring Therapeutics Revenue and Financials
- Purespring Therapeutics Highlights
- Purespring Therapeutics Business Model
- Purespring Therapeutics Risk Factors
- Purespring Therapeutics Research Report from SACRA Research
Trading Purespring Therapeutics Stock
How to invest in Purespring Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Purespring Therapeutics through EquityZen funds. These investments are made available by existing Purespring Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Purespring Therapeutics stock?
Shareholders can sell their Purespring Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 370K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
